Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (421-430 of 1,126) with videos related to

Pageof 113
Sort By:
World Journal of Urology|August 30, 2019
Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testisElio Mazzone, Sophie Knipper, Francesco A Mistretta, et al.
Urologic Oncology|February 19, 2021
Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based studyAngela Pecoraro, Marina Deuker, Giuseppe Rosiello, et al.
BMC Health Services Research|June 10, 2018
Describing perspectives of health care professionals on active surveillance for the management of prostate cancerKittie Pang, Margaret Fitch, Veronique Ouellet, et al.
European Urology Oncology|May 18, 2019
Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical CystectomyEmanuele Zaffuto, Marco Bandini, Marco Moschini, et al.
Plos One|August 17, 2010
Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancerPhilippe O Gannon, Jessica Godin-Ethier, Matthew Hassler, et al.
The Lancet. Oncology|April 13, 2026
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trialAlicia K Morgans, Kunhi Parambath Haresh, Mindaugas Jievaltas, et al.
Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2018
An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancerBodine P S I Belderbos, Ronald de Wit, Caly Chien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2015
Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer PatientsXu S Xu, Charles J Ryan, Kim Stuyckens, et al.
Urologic Oncology|March 4, 2020
Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinomaGiuseppe Rosiello, Carlotta Palumbo, Sophie Knipper, et al.
Pageof 113

Showing results (421-430 of 1,126) with videos related to

Sort By:
Pageof 113
World Journal of Urology|August 30, 2019
Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testisElio Mazzone, Sophie Knipper, Francesco A Mistretta, et al.
Urologic Oncology|February 19, 2021
Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based studyAngela Pecoraro, Marina Deuker, Giuseppe Rosiello, et al.
BMC Health Services Research|June 10, 2018
Describing perspectives of health care professionals on active surveillance for the management of prostate cancerKittie Pang, Margaret Fitch, Veronique Ouellet, et al.
European Urology Oncology|May 18, 2019
Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical CystectomyEmanuele Zaffuto, Marco Bandini, Marco Moschini, et al.
Plos One|August 17, 2010
Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancerPhilippe O Gannon, Jessica Godin-Ethier, Matthew Hassler, et al.
The Lancet. Oncology|April 13, 2026
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trialAlicia K Morgans, Kunhi Parambath Haresh, Mindaugas Jievaltas, et al.
Cancers|December 10, 2021
The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical TrialsBertrand Tombal, Arnulf Stenzl, David Cella, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2018
An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancerBodine P S I Belderbos, Ronald de Wit, Caly Chien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2015
Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer PatientsXu S Xu, Charles J Ryan, Kim Stuyckens, et al.
Urologic Oncology|March 4, 2020
Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinomaGiuseppe Rosiello, Carlotta Palumbo, Sophie Knipper, et al.
Pageof 113